Close Menu

NEW YORK (GenomeWeb) – CellMax Life's focus on developing a blood-based cell detection platform to detect pre-cancer and cancer at an early stage is one of its main differentiating points in an increasingly crowded market, a company executive said last week on the sidelines of the 37th annual JP Morgan Healthcare Conference.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.